5th International AIDS Society Conference on HIV Pathogenesis and Treatment Cape Town - July 19 - 22, 2009

NO EVIDENCE FOR RECENT ABACAVIR/LAMIVUDINE USE IN PROMOTING INFLAMMATION, ENDOTHELIAL DYSFUNCTION, HYPERCOAGULABILITY, OR INSULIN RESISTANCE IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS: A SUBSTUDY OF THE BICOMBO RANDOMIZED CLINICAL TRIAL (ISRCTN61891868)

IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOAB203

E. Martinez ¹, M. Larrousse¹, I. Perez¹, M. Loncá¹, D. Podzamczer², F. Gutierrez³, R. Deulofeu¹, R. Casamitjana¹, J. C. Reverter¹, J. Mallolas¹, J. Pich¹, J.M. Gatell¹, for the BICOMBO Study Group
¹Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain, ²Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain, ³Hospital General Universitario de Elche, Elche, Spain

BACKGROUND: Inflammation, plaque instability, and/or thrombosis are suggested mechanisms for cardiovascular disease associated with recent abacavir use in some cohort studies. To avoid bias due to HIV replication and drug prescription, we assessed 48-week changes in markers of inflammation, endothelial dysfunction, hypercoagulability, and insulin resistance in otherwise healthy, virologically suppressed HIV-infected patients randomly switched to abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC).

METHODS: Patients with no history of cardiovascular disease, no prior ABC or TDF use, and no virological failure during follow-up were included. Fasting serum high-sensitive C reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1), osteoprotegerin (OPG), adiponectin, IL-6, IL-10, TNF-α, ICAM-1, VCAM-1, selectin E and P, D-dimer, and insulin were measured. Mann-Whitney and Spearman tests were used for comparisons and correlations, respectively.

RESULTS: Eighty (46 ABC/3TC, 34 TDF/FTC) patients included. At baseline, gender (80% males), age (median 43 years), antiretroviral exposure (median 3.6 years), and Framingham score (median 4.4) were similar between groups and between patients in the substudy vs those not. There were no significant differences in baseline markers between groups. As expected, ICAM-1 and VCAM-1 (r=0.51, P<0.0001), and selectin E and P (r=0.63, P<0.0001) were correlated at baseline. At baseline, OPG, selectin E and P were also correlated with Framingham score. Median 48-week percent changes in markers between ABC/3TC and TDF/FTC groups were: CRP (-3.9 vs 0.0), MCP-1 (5.9 vs 4.0), OPG (5.1 vs - 2.8), adiponectin (-2.2 vs 15.4), ICAM-1 (6.6 vs 5.2), VCAM-1 (8.4 vs -2.0), selectin E (-0.4 vs 7.8), selectin P (4.6 vs 12.6), D-dimer (0.0 vs 0.0), and insulin (-2.5 vs 8.8) (P=0.12 for all comparisons). IL-6, IL-10, and TNF-α at baseline and 48 weeks were undetectable for most patients.

CONCLUSIONS: These results do not support a role of recent ABC/3TC use in promoting inflammation, endothelial dysfunction, hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients.

Download PDF of this abstract.

Download Power Point Presentation.

2009-07-22
MOAB203
Oral Abstract Session MOAB2 - Cardiovascular Disease: to HAART or not to HAART

Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.